AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02535572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEAST
Description: FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
Study NCT02806076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tumor puncture RFA arm
Description: Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode.
Study NCT03542799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR IL12 CART
Description: EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)
Study NCT00128388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFPP
Description: Psychoanalytic Psychotherapy for panic disorder
Study NCT02535572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RUL UB
Description: This is right unilateral ultrabrief ECT, the standard of care.
Study NCT05779371 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated-based Laughing Qigong Program
Description: The protocol of the Integrated-based Laughing Qigong Program (IB-LQP) combined laughter intervention and mental health promotion courses. It was a two-hour community activity held twice a week for six weeks. The content was 50-60 minutes of a laughter practice program and 50 minutes of mental health lectures, separated by a 10-minute break.
Study NCT00742664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
Study NCT00742664 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list control
Description: The subject will not receive active treatment during this interval.
Study NCT03948477 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pantoprazole 40mg
Description: Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.
Study NCT03948477 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matched placebo
Study NCT01174433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tryton
Description: Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
Study NCT02973880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NETILDEX™ ophthalmic gel
Description: 1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery.
Study NCT02973880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NETILDEX™ eye drops solution
Description: 1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery.
Study NCT01476202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Description: nicotine in the form of a mouth strip, lozenge and gum
Study NCT01476202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: nicotine in the form of a mouth strip, lozenge and gum
Study NCT03048383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA Injectable Product
Description: Administered to treat facial synkinesis
Study NCT03048383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA Injectable Product
Description: Administered to treat facial synkinesis
Study NCT03048383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incobotulinumtoxin A Injectable Product
Description: Administered to treat facial synkinesis
Study NCT01989208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SG1002
Description: 200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
Study NCT01989208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg capsules containing placebo will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
Study NCT03118908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amberen
Description: Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
Study NCT03118908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smart B
Description: Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
Study NCT03118908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are identical to Amberen and Smart B capsules.
Study NCT03587285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tcm+ Goserelin acetate+ Bicalutamide
Description: Autologous Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,50 mg bicalutamide administered orally daily
Study NCT03587285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tcm+Goserelin acetate+Abiraterone acetate
Description: Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,1000 mg abiraterone acetate administered orally daily plus 5 mg prednisone administered orally twice daily
Study NCT05577520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus floor augmentation
Study NCT03619057 — intervention group
Intervention type: OTHER
Intervention: General anesthesia with laryngeal mask i-gel
Description: General anesthesia with laryngeal mask i-gel
Study NCT00670943 — intervention group
Intervention type: OTHER
Intervention: Platelet function testing
Study NCT00993226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine Treatment 1a
Description: 5.0 ml
Study NCT03651947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1206
Description: subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
Study NCT03651947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva®
Description: subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
Study NCT03433781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: All patients will receive at least 1 cycle of treatment (4 weeks) of Vitamin C as a continuous intravenous infusion (CIVI). Patients with clinical benefit (CR, PR, or SD) then will undergo a second 4-week cycle of treatment. Patients to receive a maximum of 16 weeks of treatment (4 cycles). If a patient progress after receiving a cycle of treatment then the patient will be withdrawn from the study. Patients will be maintained on 1 gram oral Vitamin C daily from the end of the CIVI until the beginning of the next cycle (from day 6 till 28).
Study NCT00110994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib, 400 mg, 2 tablets (200 mg each) po (per os) bid (twice daily) Study days 1-21
Study NCT00110994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21
Study NCT00110994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine, 1000 mg/m\^2 intravenous on Study Day 1
Study NCT00110994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine, 1000 mg/m\^2 intravenous on Study Day 1
Study NCT02002702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: Intravenous infusion
Study NCT02002702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01845714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Cross Linking
Study NCT01845714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Cross Linking combined with topoguided PRK
Study NCT00486447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 64 Channel VCT
Description: cardiac CT angiography exam
Study NCT00128388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: Applied Relaxation Training
Study NCT01816607 — intervention group
Intervention type: PROCEDURE
Intervention: new functional magnetic resonance imaging (MRI) protocols
Description: diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI
Study NCT04709887 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Wound treatment
Description: According to the guidelines and recommendations of the International Diabetic Foot Working Group, ulcer surface debridement, negative pressure suction drainage, and routine dressing were performed until the wound healed or the end of the trial.
Study NCT00993226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SABER-Bupivacaine Treatment 1b
Description: 5.0 ml
Study NCT00993226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl Treatment 1c
Description: 40 ml
Study NCT00993226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine Treatment 2a
Description: 7.5 ml
Study NCT00993226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SABER-Bupivacaine Treatment 2b
Description: 7.5 ml
Study NCT00993226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl Treatment 2c
Description: 40 ml
Study NCT02542267 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gore VIABAHN Endoprosthesis
Study NCT04351139 — intervention group
Intervention type: OTHER
Intervention: modification of the planned therapeutic management
Description: to evaluate the changes in therapeutic management, during the COVID-19 pandemic, of patients suffering from gynecological cancers
Study NCT02631707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: The intervention diet is higher in protein than the control diet.
Study NCT01799876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Cell
Study NCT01799876 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard microfracture arthroscopic surgery
Study NCT01054833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needleless mid-urethral sling
Description: The Needleless® sling is intended for use in women as a tension free, sub-urethral slings for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The Needleless sling is a macroporous, monofilament, knitted polypropylene featuring 'Pocket Positioning Anchors' which allow sling placement without needle introducers; thus eliminating a complicated aspect of the surgery (TVT/TOT) and reducing the potential for bladder injury or inguinal pain that can occur during transobturator needle passage. The Needleless sling was approved by KFDA, and now is available in worldwide including Korea.
Study NCT02909621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FLEXOFYTOL®
Description: The product FLEXOFYTOL® is bio-optimized curcumin.
Study NCT02909621 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study NCT04278807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia - Nerve Blocks
Description: Regional Anesthesia and ultrasound-guided nerve blocks
Study NCT03176316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone is an opioid antagonist (i.e., a medication used to reverse or reduce the effects of opioids)
Study NCT00531960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg, PO, daily
Study NCT00531960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg, IV, Day 1 of Cycles 1 through 7
Study NCT00531960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, IV, Day 1 of Cycles 1 through 7
Study NCT00531960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard platinum-based chemotherapy
Description: At the discretion of the investigator
Study NCT03486392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 1
Description: Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.
Study NCT03486392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 2
Description: Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.
Study NCT03486392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 3
Description: Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.
Study NCT03486392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
Study NCT03486392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo SC once-weekly until Week 26.
Study NCT03803527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal String Test
Description: An EST will be performed for a 1hour sampling period on the same day as the scheduled clinic visit. Subjects will be asked to swallow a capsule and the attached EST string will be taped to the cheek with tegaderm tape. At the completion of the 1-hour sampling period, the EST will be removed and it will immediately be processed and cryopreserved for metabolomics profiling.
Study NCT03034603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutri-jelly with PEITC
Description: Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
Study NCT03034603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutri-jelly
Description: Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
Study NCT04371367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avdoralimab
Description: intravenous administration of avdoralimab
Study NCT04371367 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous administration of placebo
Study NCT00679458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine and low-dose naloxone
Description: each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
Study NCT00679458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine alone
Description: each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
Study NCT03544112 — intervention group
Intervention type: BEHAVIORAL
Intervention: Employ a multifaceted approach to facilitate clinical protocol implementation
Description: Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
Study NCT03544112 — intervention group
Intervention type: DRUG
Intervention: Initiate BUP (SL-BUP or XR-BUP) in the ED
Description: The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
Study NCT03822481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Construal Diary
Description: A Mindful Eating Intervention
Study NCT04325477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nolix Device
Description: The Nolix device is a single use, dynamic, and soft flexible intra-vaginal device for temporary management of SUI
Study NCT01433250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: (10mg/kg i.v.).
Study NCT04083625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbetocin 100 mcg
Description: a 10 cm syringe containing 100 mcg carbetocin just before skin incision of myomectomy.
Study NCT04083625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a 10 cm syringe normal saline IV given just before skin incision of myomectomy.
Study NCT03632954 — intervention group
Intervention type: DEVICE
Intervention: ACell Arm
Description: Cytal® Wound Matrix and/or MicroMatrix®
Study NCT03543072 — intervention group
Intervention type: DRUG
Intervention: Bisphosphonates
Description: a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases
Study NCT02338570 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus
Description: Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
Study NCT02747472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP-A
Description: GIP receptor antagonist
Study NCT02747472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP(1-42)
Description: GIP receptor agonist
Study NCT02747472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP(1-42)
Description: GIP receptor agonist
Study NCT02747472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT01937429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with blue Indigo Carmin®
Study NCT03982550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Periodized Resistance Training
Description: Mesocycle I (weeks 1-4) will emphasize muscular hypertrophy to develop a muscular and metabolic base for more intense training in later phases. Training bouts will consist of 4-6 resistance exercises with 2-4 sets per exercise and 8-10 repetitions per set. Mesocycles II (weeks 5-8) and III (weeks 9-12) will emphasize strength development. Training bouts will consist of 4-6 resistance exercises with 3-5 sets per exercise, 4-6 repetitions per set, and linear increases in intensity over time. These parameters were chosen to maximize performance on 4-6 repetition maximum (RM) testing post-intervention, according to the principle of specificity - i.e. specific adaptation to imposed demands.The training loads used will be individually progressed in a safe and effective manner, in order to employ a progressive overload/challenge to the neuromuscular system and elicit the greatest training-induced neuromuscular adaptations possible.
Study NCT01712347 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab will be administered as per approved label.
Study NCT01937429 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy with insufflation of air